210 related articles for article (PubMed ID: 25068506)
1. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.
Yang K; Woodhead JL; Watkins PB; Howell BA; Brouwer KL
Clin Pharmacol Ther; 2014 Nov; 96(5):589-98. PubMed ID: 25068506
[TBL] [Abstract][Full Text] [Related]
2. Application of systems pharmacology to explore mechanisms of hepatotoxicity.
Shon J; Abernethy DR
Clin Pharmacol Ther; 2014 Nov; 96(5):536-7. PubMed ID: 25336266
[TBL] [Abstract][Full Text] [Related]
3. Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone.
Cheng Y; Chen S; Freeden C; Chen W; Zhang Y; Abraham P; Nelson DM; Humphreys WG; Gan J; Lai Y
J Pharmacol Exp Ther; 2017 Sep; 362(3):385-394. PubMed ID: 28645914
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.
Funk C; Pantze M; Jehle L; Ponelle C; Scheuermann G; Lazendic M; Gasser R
Toxicology; 2001 Oct; 167(1):83-98. PubMed ID: 11557132
[TBL] [Abstract][Full Text] [Related]
5. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
Funk C; Ponelle C; Scheuermann G; Pantze M
Mol Pharmacol; 2001 Mar; 59(3):627-35. PubMed ID: 11179459
[TBL] [Abstract][Full Text] [Related]
6. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.
Jemnitz K; Veres Z; Vereczkey L
Toxicol Sci; 2010 May; 115(1):80-8. PubMed ID: 20147439
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
Masubuchi Y
Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
[TBL] [Abstract][Full Text] [Related]
8. Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition.
Cepa S; Potter D; Wong L; Schutt L; Tarrant J; Pang J; Zhang X; Andaya R; Salphati L; Ran Y; An L; Morgan R; Maher J
Toxicol Appl Pharmacol; 2018 Jan; 338():204-213. PubMed ID: 29146462
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone Inhibits Bile Acid Amidation: A Possible Risk Factor for Liver Injury.
Ogimura E; Nakagawa T; Deguchi J; Sekine S; Ito K; Bando K
Toxicol Sci; 2017 Aug; 158(2):347-355. PubMed ID: 28486596
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of troglitazone hepatotoxicity.
Smith MT
Chem Res Toxicol; 2003 Jun; 16(6):679-87. PubMed ID: 12807350
[No Abstract] [Full Text] [Related]
11. Effect of thiazolidinediones on bile acid transport in rat liver.
Snow KL; Moseley RH
Life Sci; 2007 Jan; 80(8):732-40. PubMed ID: 17126857
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.
Yang K; Brouwer KL
Drug Metab Dispos; 2014 Jul; 42(7):1219-26. PubMed ID: 24799397
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.
Tettey JN; Maggs JL; Rapeport WG; Pirmohamed M; Park BK
Chem Res Toxicol; 2001 Aug; 14(8):965-74. PubMed ID: 11511170
[TBL] [Abstract][Full Text] [Related]
14. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Nozawa T; Sugiura S; Nakajima M; Goto A; Yokoi T; Nezu J; Tsuji A; Tamai I
Drug Metab Dispos; 2004 Mar; 32(3):291-4. PubMed ID: 14977862
[TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.
Lee JK; Marion TL; Abe K; Lim C; Pollock GM; Brouwer KL
J Pharmacol Exp Ther; 2010 Jan; 332(1):26-34. PubMed ID: 19801447
[TBL] [Abstract][Full Text] [Related]
16. Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity.
Generaux G; Lakhani VV; Yang Y; Nadanaciva S; Qiu L; Riccardi K; Di L; Howell BA; Siler SQ; Watkins PB; Barton HA; Aleo MD; Shoda LKM
Pharmacol Res Perspect; 2019 Dec; 7(6):e00523. PubMed ID: 31624633
[TBL] [Abstract][Full Text] [Related]
17. Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes.
Marion TL; Perry CH; St Claire RL; Yue W; Brouwer KL
Toxicol Sci; 2011 Apr; 120(2):371-80. PubMed ID: 21262925
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Saha S; New LS; Ho HK; Chui WK; Chan EC
Toxicol Lett; 2010 Feb; 192(2):141-9. PubMed ID: 19854250
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism.
Jia R; Oda S; Tsuneyama K; Urano Y; Yokoi T
J Appl Toxicol; 2019 Nov; 39(11):1541-1556. PubMed ID: 31294483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
